AEON Biopharma stockholders elect two Class I directors and approve potential Daewoong issuance at annual meeting

AEON Biopharma, Inc.

Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.
Stockholders approved potential issuance of 20%+ of Class A common stock to Daewoong Pharmaceuticals at below-market value, a change-of-control measure.
Ratification of KPMG LLP as auditor for fiscal 2024 passed with 25,491,112 votes for.
All three proposals received sufficient votes; broker non-votes were 675,301 on first two proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.